Cyclo Therapeutics (CYTH) PT Lowered to $0.95 at Ascendiant Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
H.C. Wainwright Downgrades Cyclo Therapeutics (CYTH) to Neutral
August 23, 2024 6:06 AM EDT(Updated - August 23, 2024 6:34 AM EDT)
H.C. Wainwright analyst Swayampakula Ramakanth downgraded Cyclo Therapeutics (NASDAQ: CYTH) from Buy to Neutral with a price target of $0.95 (from $3.00).
The analyst comments "Rafael Holdings to acquire Cyclo. On August 22, Cyclo Therapeutics announced that... More
Rafael Holdings (RFL) and Cyclo Therapeutics (CYTH) Enter into Definitive Merger Agreement
August 22, 2024 6:50 AM EDTRafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (Nasdaq: CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics shareholders, based on an exchange ratio valuing Cyclo Therapeutics shares at $.95 per share and Rafael Holdings at its cash value combined with the value of its marketable... More
